TV News LIES

Sunday, Feb 01st

Last update09:46:15 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


There’s A Treatment For Heroin Addiction That Actually Works. Why Aren’t We Using It?

Heroin addiction cureFor addicts, cravings override all normal rules of behavior. In interviews throughout Northern Kentucky, addicts and...

White House announces precision medicine initiative

Obaba personal medicine initiativeA new initiative announced by the President Barack Obama Friday will see renewed efforts to collect...

CDC: Flu hospitalizations for elderly highest ever recorded

Flu cases worse than everThe CDC warned the 2014-15 flu season would be a bad one and new numbers from...

American Academy of Pediatrics says medical marijuana could be good for some kids

medical marijuanaThe American Academy of Pediatrics (AAP), which has the largest pediatric publishing program in the world,...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!